Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • US shares rebound on Friday, XJO to open higher
    • Market Update

    US shares rebound on Friday, XJO to open higher

    The XJO is expected to open higher following a recovery in the U.S on Friday. Their futures are flat. For a moment there it looked like the U.S was going to break lower with its strong pullback last Thursday. However, during their Friday session they were able to retake much of the previous session’s losses

    Read More
    Public
  • PYC Therapeutics receives Orphan Drug Designation for ADOA treatment
    • News

    PYC Therapeutics receives Orphan Drug Designation for ADOA treatment

    PYC Therapeutics (ASX: PYC), a clinical-stage biotechnology company, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation (ODD) to its investigational drug candidate, PYC-001. This precision therapy is designed to treat Autosomal Dominant Optic Atrophy (ADOA), a rare and progressive blinding eye disease. This designation is expected

    Read More
    Public
  • Understanding the Federal Budget from an investor perspective
    • Opinion

    Understanding the Federal Budget from an investor perspective

    The Australian Federal Government recently handed down the 2024-25 Australian Federal Budget – it was all about a bigger government role and fiscal policy support. The government handed down a second consecutive surplus thanks largely to higher commodity prices and ongoing strength in the labour market. Below we discuss key components of the budget.  Big

    Read More
    Public
  • US shares reverse from all-time highs, XJO to fall
    • Market Update

    US shares reverse from all-time highs, XJO to fall

    The XJO is set to tumble again today following a pullback in the U.S overnight. Their futures are flat. Our market should retreat back to the comfort of the 50 day MA on open this morning, which comes in at roughly 7,740. We may selldown further to 7,700 support if things get worse come open,

    Read More
    Public
  • PlaySide Studios to develop Game of Thrones strategy game with Warner Bros
    • News

    PlaySide Studios to develop Game of Thrones strategy game with Warner Bros

    Winter is coming, and a Game of Thrones-themed game by video game developer PlaySide Studios (ASX: PLY) is being developed with it.  The Company has teamed up with Warner Bros. Interactive Entertainment and HBO to develop a multiplayer strategy game based on the Emmy Award- and Golden Globe-winning Game of Thrones series.  This new premium

    Read More
    Public
  • EROAD’s price hikes boost cash flow, expects cash flow positivity
    • News

    EROAD’s price hikes boost cash flow, expects cash flow positivity

    After grappling with significant losses, transportation technology services company EROAD (ASX: ERD) appears to be bouncing back. It has revealed its FY24 results, ending March 2024, as it enters FY25 with high hopes. EROAD achieved a notable improvement in free cash flow, turning positive at $1.3 million, a significant rebound from the negative $29.9 million

    Read More
    Public
  • «
  • ‹
  • 76
  • 77
  • 78
  • 79
  • 80
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.